Skip to main content
Erschienen in: Current Cardiology Reports 1/2013

01.01.2013 | New Therapies for Cardiovascular Disease (K Mahaffey, Section Editor)

Impediments to Adherence to Post Myocardial Infarction Medications

verfasst von: Nihar R. Desai, Niteesh K. Choudhry

Erschienen in: Current Cardiology Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Non-adherence to evidence-based medications is a major public health problem. Less than 50 % of patients with coronary artery disease adhere to their prescribed therapies and this has important implications for morbidity, mortality, and health care spending. Like most complex behaviors, medication non-adherence is not solely the result of poor patient choices. Rather, there are myriad potential contributors attributable to patients, health care providers, and, more broadly, the health care system. Interventions including patient education and behavioral modification, improving patient-physician communication, and eliminating copayments for preventive pharmacotherapy have all been studied. Clinicians play a critical role in helping improve adherence and assessment of adherence must become a standard component of each clinical encounter. Ultimately, given the various etiologies that contribute to non-adherence, achieving meaningful gains will undoubtedly require payors, providers, and policymakers to develop, rigorously evaluate, and systematically deploy strategies that address key patient, clinician, and health system factors.
Literatur
1.
Zurück zum Zitat DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Medical Care. 2004;42:200–9.PubMedCrossRef DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Medical Care. 2004;42:200–9.PubMedCrossRef
3.
Zurück zum Zitat Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.PubMedCrossRef Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.PubMedCrossRef
4.••
Zurück zum Zitat Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215. This report from the American Heart Association offers important statistics about the burden of CAD and acute myocardial infarction in the United States.PubMedCrossRef Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215. This report from the American Heart Association offers important statistics about the burden of CAD and acute myocardial infarction in the United States.PubMedCrossRef
5.
Zurück zum Zitat Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the acc/aha 2004 guidelines for the management of patients with st-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with st-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation. 2008;117:296–329.PubMedCrossRef Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 focused update of the acc/aha 2004 guidelines for the management of patients with st-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: Developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with st-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation. 2008;117:296–329.PubMedCrossRef
6.
Zurück zum Zitat Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. Deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–98.PubMedCrossRef Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. Deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–98.PubMedCrossRef
7.
Zurück zum Zitat Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey Jr DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–e157.PubMedCrossRef Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey Jr DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1–e157.PubMedCrossRef
8.
Zurück zum Zitat Choudhry NK, Winkelmayer WC. Medication adherence after myocardial infarction: A long way left to go. J Gen Intern Med. 2008;23:216–8.PubMedCrossRef Choudhry NK, Winkelmayer WC. Medication adherence after myocardial infarction: A long way left to go. J Gen Intern Med. 2008;23:216–8.PubMedCrossRef
9.•
Zurück zum Zitat Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010;121:586–613. This report outlines the American Heart Association's 2020 Goal.PubMedCrossRef Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association's strategic impact goal through 2020 and beyond. Circulation. 2010;121:586–613. This report outlines the American Heart Association's 2020 Goal.PubMedCrossRef
10.
Zurück zum Zitat Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2:CD000011. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2:CD000011.
11.
Zurück zum Zitat Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986;24:67–74.PubMedCrossRef Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Medical Care. 1986;24:67–74.PubMedCrossRef
12.
Zurück zum Zitat Chisholm-Burns MA, Spivey CA, Garrett C, McGinty H, Mulloy LL. Impact of clinical pharmacy services on renal transplant recipients' adherence and outcomes. Patient Preference Adherence. 2008;2:287–92.CrossRef Chisholm-Burns MA, Spivey CA, Garrett C, McGinty H, Mulloy LL. Impact of clinical pharmacy services on renal transplant recipients' adherence and outcomes. Patient Preference Adherence. 2008;2:287–92.CrossRef
13.
Zurück zum Zitat Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457–64.PubMed Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457–64.PubMed
14.
Zurück zum Zitat Peterson ED, Shah BR, Parsons L, Pollack Jr CV, French WJ, Canto JG, et al. Trends in quality of care for patients with acute myocardial infarction in the national registry of myocardial infarction from 1990 to 2006. Am Heart J. 2008;156:1045–55.PubMedCrossRef Peterson ED, Shah BR, Parsons L, Pollack Jr CV, French WJ, Canto JG, et al. Trends in quality of care for patients with acute myocardial infarction in the national registry of myocardial infarction from 1990 to 2006. Am Heart J. 2008;156:1045–55.PubMedCrossRef
15.
Zurück zum Zitat Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:1028–36.PubMedCrossRef Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation. 2008;117:1028–36.PubMedCrossRef
16.•
Zurück zum Zitat Fischer MA, Choudhry NK, Brill G, Avorn J, Schneeweiss S, Hutchins D, et al. Trouble getting started: Predictors of primary medication nonadherence. Am J Med. 2011;124:1081–e1089–22. This study examines the prevalence, predictors, and outcomes of primary nonadherence.PubMedCrossRef Fischer MA, Choudhry NK, Brill G, Avorn J, Schneeweiss S, Hutchins D, et al. Trouble getting started: Predictors of primary medication nonadherence. Am J Med. 2011;124:1081–e1089–22. This study examines the prevalence, predictors, and outcomes of primary nonadherence.PubMedCrossRef
17.
Zurück zum Zitat Tricoci P, Roe MT, Mulgund J, Newby LK, Smith Jr SC, Pollack Jr CV, et al. Clopidogrel to treat patients with non-st-segment elevation acute coronary syndromes after hospital discharge. Archives of Internal Medicine. 2006;166:806–11.PubMedCrossRef Tricoci P, Roe MT, Mulgund J, Newby LK, Smith Jr SC, Pollack Jr CV, et al. Clopidogrel to treat patients with non-st-segment elevation acute coronary syndromes after hospital discharge. Archives of Internal Medicine. 2006;166:806–11.PubMedCrossRef
18.
Zurück zum Zitat Ganz DA, Kuntz KM, Benner JS, Avorn J. Correction: cost-effectiveness of statins in older patients with myocardial infarction. Ann Intern Med. 2002;136:635.PubMed Ganz DA, Kuntz KM, Benner JS, Avorn J. Correction: cost-effectiveness of statins in older patients with myocardial infarction. Ann Intern Med. 2002;136:635.PubMed
19.
Zurück zum Zitat Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med. 2008;23:115–21.PubMedCrossRef Akincigil A, Bowblis JR, Levin C, Jan S, Patel M, Crystal S. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med. 2008;23:115–21.PubMedCrossRef
20.
Zurück zum Zitat Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–7.PubMedCrossRef Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462–7.PubMedCrossRef
21.
Zurück zum Zitat Kramer JM, Hammill B, Anstrom KJ, Fetterolf D, Snyder R, Charde JP, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152:454–e451–8.PubMedCrossRef Kramer JM, Hammill B, Anstrom KJ, Fetterolf D, Snyder R, Charde JP, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J. 2006;152:454–e451–8.PubMedCrossRef
22.
Zurück zum Zitat Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–61.PubMedCrossRef Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–61.PubMedCrossRef
23.
Zurück zum Zitat Choudhry NK, Setoguchi S, Levin R, Winkelmayer WC, Shrank WH. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008;17:1189–96.PubMedCrossRef Choudhry NK, Setoguchi S, Levin R, Winkelmayer WC, Shrank WH. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008;17:1189–96.PubMedCrossRef
24.
Zurück zum Zitat Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203–12.PubMedCrossRef Newby LK, LaPointe NM, Chen AY, Kramer JM, Hammill BG, DeLong ER, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113:203–12.PubMedCrossRef
25.•
Zurück zum Zitat Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK. A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med. 2011;26:1479–91. This review discusses adherence to cardiovascular medications in resource-limited settings.PubMedCrossRef Bowry AD, Shrank WH, Lee JL, Stedman M, Choudhry NK. A systematic review of adherence to cardiovascular medications in resource-limited settings. J Gen Intern Med. 2011;26:1479–91. This review discusses adherence to cardiovascular medications in resource-limited settings.PubMedCrossRef
26.
Zurück zum Zitat Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–86.PubMedCrossRef Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–86.PubMedCrossRef
27.
Zurück zum Zitat Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48.PubMedCrossRef Ho PM, Magid DJ, Masoudi FA, McClure DL, Rumsfeld JS. Adherence to cardioprotective medications and mortality among patients with diabetes and ischemic heart disease. BMC Cardiovasc Disord. 2006;6:48.PubMedCrossRef
28.
Zurück zum Zitat Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772–9.PubMedCrossRef Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155:772–9.PubMedCrossRef
30.
Zurück zum Zitat Sabate E. Adherence to long term therapies: evidence for action. Geneva. Switzerland: World Health Organization; 2003. Accessed August 19, 2012. Sabate E. Adherence to long term therapies: evidence for action. Geneva. Switzerland: World Health Organization; 2003. Accessed August 19, 2012.
31.
Zurück zum Zitat Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–52.PubMedCrossRef Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–52.PubMedCrossRef
32.•
Zurück zum Zitat Shrank WH, Liberman JN, Fischer MA, Kilabuk E, Girdish C, Cutrona S, et al. Are caregivers adherent to their own medications? J Am Pharm Assoc (2003). 2011;51:492–8. This study examines adherence patterns among caregivers. Shrank WH, Liberman JN, Fischer MA, Kilabuk E, Girdish C, Cutrona S, et al. Are caregivers adherent to their own medications? J Am Pharm Assoc (2003). 2011;51:492–8. This study examines adherence patterns among caregivers.
33.•
Zurück zum Zitat Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48:196–202. This study examines patient, physician, and payment predictors of statin adherence.PubMedCrossRef Chan DC, Shrank WH, Cutler D, Jan S, Fischer MA, Liu J, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48:196–202. This study examines patient, physician, and payment predictors of statin adherence.PubMedCrossRef
34.•
Zurück zum Zitat Fischer MA, Choudhry NK, Brill G, Avorn J, Schneeweiss S, Hutchins D, et al. Trouble getting started: predictors of primary medication nonadherence. Am J Med. 2011;124:1081.e1089–1081.e1022. This study examines the prevalence, predictors, and outcomes of primary nonadherence. Fischer MA, Choudhry NK, Brill G, Avorn J, Schneeweiss S, Hutchins D, et al. Trouble getting started: predictors of primary medication nonadherence. Am J Med. 2011;124:1081.e1089–1081.e1022. This study examines the prevalence, predictors, and outcomes of primary nonadherence.
35.•
Zurück zum Zitat Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: Systematic review of qualitative research. BMJ. 2012;345:e3953. Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: Systematic review of qualitative research. BMJ. 2012;345:e3953.
36.
Zurück zum Zitat Aikens JE, Piette JD. Diabetic patients' medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments. Diabetes Care. 2009;32:19–24.PubMedCrossRef Aikens JE, Piette JD. Diabetic patients' medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments. Diabetes Care. 2009;32:19–24.PubMedCrossRef
37.•
Zurück zum Zitat Kulik A, Shrank WH, Levin R, Choudhry NK. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011;107:1409–14. This study examines the impact of coronary revascularizatin on adherence to statin therapy.PubMedCrossRef Kulik A, Shrank WH, Levin R, Choudhry NK. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011;107:1409–14. This study examines the impact of coronary revascularizatin on adherence to statin therapy.PubMedCrossRef
38.
Zurück zum Zitat Jiang W, Glassman A, Krishnan R, O'Connor CM, Califf RM. Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J. 2005;150:54–78.PubMedCrossRef Jiang W, Glassman A, Krishnan R, O'Connor CM, Califf RM. Depression and ischemic heart disease: what have we learned so far and what must we do in the future? Am Heart J. 2005;150:54–78.PubMedCrossRef
39.
Zurück zum Zitat Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the heart and soul study. Arch Intern Med. 2005;165:2508–13.PubMedCrossRef Gehi A, Haas D, Pipkin S, Whooley MA. Depression and medication adherence in outpatients with coronary heart disease: findings from the heart and soul study. Arch Intern Med. 2005;165:2508–13.PubMedCrossRef
40.
Zurück zum Zitat Rieckmann N, Gerin W, Kronish IM, Burg MM, Chaplin WF, Kong G, et al. Course of depressive symptoms and medication adherence after acute coronary syndromes: An electronic medication monitoring study. J Am Coll Cardiol. 2006;48:2218–22.PubMedCrossRef Rieckmann N, Gerin W, Kronish IM, Burg MM, Chaplin WF, Kong G, et al. Course of depressive symptoms and medication adherence after acute coronary syndromes: An electronic medication monitoring study. J Am Coll Cardiol. 2006;48:2218–22.PubMedCrossRef
41.
Zurück zum Zitat Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.PubMed Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22–33.PubMed
42.
Zurück zum Zitat Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31:213–24.PubMedCrossRef Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008;31:213–24.PubMedCrossRef
43.
Zurück zum Zitat Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25:885–92.PubMedCrossRef Chapman RH, Petrilla AA, Benner JS, Schwartz JS, Tang SS. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25:885–92.PubMedCrossRef
44.
Zurück zum Zitat Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–9.PubMedCrossRef Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713–9.PubMedCrossRef
45.
46.
Zurück zum Zitat Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80 %. BMJ. 2003;326:1419.PubMedCrossRef Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80 %. BMJ. 2003;326:1419.PubMedCrossRef
47.
Zurück zum Zitat Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167:847–52.PubMedCrossRef Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167:847–52.PubMedCrossRef
48.••
Zurück zum Zitat Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, et al. Medication adherence: a call for action. Am Heart J. 2011;162:412–24. This comprehensive review examines the prevalence, predictors, and interventions to address non-adherence.PubMedCrossRef Bosworth HB, Granger BB, Mendys P, Brindis R, Burkholder R, Czajkowski SM, et al. Medication adherence: a call for action. Am Heart J. 2011;162:412–24. This comprehensive review examines the prevalence, predictors, and interventions to address non-adherence.PubMedCrossRef
49.
Zurück zum Zitat Choudhry NK, Brennan T, Toscano M, Spettell C, Glynn RJ, Rubino M, et al. Rationale and design of the post-mi freee trial: a randomized evaluation of first-dollar drug coverage for post–myocardial infarction secondary preventive therapies. Am Heart J. 2008;156:31–6.PubMedCrossRef Choudhry NK, Brennan T, Toscano M, Spettell C, Glynn RJ, Rubino M, et al. Rationale and design of the post-mi freee trial: a randomized evaluation of first-dollar drug coverage for post–myocardial infarction secondary preventive therapies. Am Heart J. 2008;156:31–6.PubMedCrossRef
50.
Zurück zum Zitat Rector TS, Venus PJ. Do drug benefits help medicare beneficiaries afford prescribed drugs? Health Aff (Millwood). 2004;23:213–22.CrossRef Rector TS, Venus PJ. Do drug benefits help medicare beneficiaries afford prescribed drugs? Health Aff (Millwood). 2004;23:213–22.CrossRef
51.
Zurück zum Zitat Felland LE, Reschovsky JD. More nonelderly Americans face problems affording prescription drugs. Tracking Rep/Center for Studying Health System Change. 2009:1–4. Felland LE, Reschovsky JD. More nonelderly Americans face problems affording prescription drugs. Tracking Rep/Center for Studying Health System Change. 2009:1–4.
52.
Zurück zum Zitat Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by medicare enrollees: does type of drug coverage matter? Health Aff (Millwood). 2001;20:276–86.CrossRef Adams AS, Soumerai SB, Ross-Degnan D. Use of antihypertensive drugs by medicare enrollees: does type of drug coverage matter? Health Aff (Millwood). 2001;20:276–86.CrossRef
53.•
Zurück zum Zitat Polinski JM, Shrank WH, Glynn RJ, Huskamp HA, Roebuck MC, Schneeweiss S. Beneficiaries with cardiovascular disease and thepart d coverage gap. Circ Cardiovasc Qual Outcomes. 2012;5:387–95. This study explores the relationship between medication cost and adherence among patients with cardiovascular disease.PubMedCrossRef Polinski JM, Shrank WH, Glynn RJ, Huskamp HA, Roebuck MC, Schneeweiss S. Beneficiaries with cardiovascular disease and thepart d coverage gap. Circ Cardiovasc Qual Outcomes. 2012;5:387–95. This study explores the relationship between medication cost and adherence among patients with cardiovascular disease.PubMedCrossRef
54.
Zurück zum Zitat Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119:390–7.PubMedCrossRef Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119:390–7.PubMedCrossRef
55.
Zurück zum Zitat Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344–50.PubMedCrossRef Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344–50.PubMedCrossRef
56.
Zurück zum Zitat Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61–9.PubMedCrossRef Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298:61–9.PubMedCrossRef
57.•
Zurück zum Zitat Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171:814–22. This study highlights the impact of therapeutic complexity on adherence, demonstrating that beyond number of medications, refill consolidation and number of different prescribers have important effects on adherence.PubMedCrossRef Choudhry NK, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171:814–22. This study highlights the impact of therapeutic complexity on adherence, demonstrating that beyond number of medications, refill consolidation and number of different prescribers have important effects on adherence.PubMedCrossRef
58.
Zurück zum Zitat Smith DH, Kramer JM, Perrin N, Platt R, Roblin DW, Lane K, et al. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med. 2008;168:477–83.PubMedCrossRef Smith DH, Kramer JM, Perrin N, Platt R, Roblin DW, Lane K, et al. A randomized trial of direct-to-patient communication to enhance adherence to beta-blocker therapy following myocardial infarction. Arch Intern Med. 2008;168:477–83.PubMedCrossRef
59.•
Zurück zum Zitat Ito K, Shrank WH, Avorn J, Patrick AR, Brennan TA, Antman EM, et al. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. Health Serv Res. (in press). This study demonstrates that interventions that improve adherence post myocardial infarction are cost-saving. Ito K, Shrank WH, Avorn J, Patrick AR, Brennan TA, Antman EM, et al. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction. Health Serv Res. (in press). This study demonstrates that interventions that improve adherence post myocardial infarction are cost-saving.
60.
Zurück zum Zitat Choudhry NK, Avorn J, Antman EM, Schneeweiss S, Shrank WH. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood). 2007;26:186–94.CrossRef Choudhry NK, Avorn J, Antman EM, Schneeweiss S, Shrank WH. Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Aff (Millwood). 2007;26:186–94.CrossRef
61.
Zurück zum Zitat Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post–myocardial infarction medicare beneficiaries. Circulation. 2008;117:1261–8.PubMedCrossRef Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH. Cost-effectiveness of providing full drug coverage to increase medication adherence in post–myocardial infarction medicare beneficiaries. Circulation. 2008;117:1261–8.PubMedCrossRef
62.
Zurück zum Zitat Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27:103–12.CrossRef Chernew ME, Shah MR, Wegh A, Rosenberg SN, Juster IA, Rosen AB, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27:103–12.CrossRef
63.••
Zurück zum Zitat Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–97. This randomized trial of full coverage vs standard coverage for preventive medications after myocardial infarction demonstrates that the former was associated with improvements in adherence and major vascular events without increasing costs.PubMedCrossRef Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365:2088–97. This randomized trial of full coverage vs standard coverage for preventive medications after myocardial infarction demonstrates that the former was associated with improvements in adherence and major vascular events without increasing costs.PubMedCrossRef
64.
Zurück zum Zitat Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009;122:961 e967–913. Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med. 2009;122:961 e967–913.
65.•
Zurück zum Zitat Kwan G, Balady GJ. Cardiac rehabilitation 2012: advancing the field through emerging science. Circulation. 2012;125:e369–73. This is a review of the benefits of cardiac rehabilitation.PubMedCrossRef Kwan G, Balady GJ. Cardiac rehabilitation 2012: advancing the field through emerging science. Circulation. 2012;125:e369–73. This is a review of the benefits of cardiac rehabilitation.PubMedCrossRef
66.
Zurück zum Zitat Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540–50.PubMedCrossRef Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540–50.PubMedCrossRef
67.•
Zurück zum Zitat Cutrona SL, Choudhry NK, Fischer MA, Servi AD, Stedman M, Liberman JN, et al. Targeting cardiovascular medication adherence interventions. J Am Pharmts Assoc. 2012;52:381–97. This study examines various approaches to improving adherence, finding that targetted interventions are more effective than broad interventions.CrossRef Cutrona SL, Choudhry NK, Fischer MA, Servi AD, Stedman M, Liberman JN, et al. Targeting cardiovascular medication adherence interventions. J Am Pharmts Assoc. 2012;52:381–97. This study examines various approaches to improving adherence, finding that targetted interventions are more effective than broad interventions.CrossRef
68.•
Zurück zum Zitat Cutrona SL, Choudhry NK, Fischer MA, Servi A, Liberman JN, Brennan TA, et al. Modes of delivery for interventions to improve cardiovascular medication adherence. Am J Manage Care. 2010;16:929–42. This study examines the impact of different modes and locations of adherence interventions. Cutrona SL, Choudhry NK, Fischer MA, Servi A, Liberman JN, Brennan TA, et al. Modes of delivery for interventions to improve cardiovascular medication adherence. Am J Manage Care. 2010;16:929–42. This study examines the impact of different modes and locations of adherence interventions.
69.•
Zurück zum Zitat Lambert-Kerzner A, Del Giacco EJ, Fahdi IE, Bryson CL, Melnyk SD, Bosworth HB, et al. Patient-centered adherence intervention after acute coronary syndrome hospitalization. Circ Cardiovasc Qual Outcomes. 2012;5:571–6. This paper describes an ongoing trial of a multifaceted intervention to improve adherence after myocardial infarction.PubMedCrossRef Lambert-Kerzner A, Del Giacco EJ, Fahdi IE, Bryson CL, Melnyk SD, Bosworth HB, et al. Patient-centered adherence intervention after acute coronary syndrome hospitalization. Circ Cardiovasc Qual Outcomes. 2012;5:571–6. This paper describes an ongoing trial of a multifaceted intervention to improve adherence after myocardial infarction.PubMedCrossRef
70.•
Zurück zum Zitat Choudhry NK. Promoting persistence: improving adherence through choice of drug class. Circulation. 2011;123:1584–6. This paper highlights the impact of provider prescribing choice on medication adherence.PubMedCrossRef Choudhry NK. Promoting persistence: improving adherence through choice of drug class. Circulation. 2011;123:1584–6. This paper highlights the impact of provider prescribing choice on medication adherence.PubMedCrossRef
71.
Zurück zum Zitat Peters E, Dieckmann N, Dixon A, Hibbard JH, Mertz CK. Less is more in presenting quality information to consumers. Med Care ResRev MCRR. 2007;64:169–90.CrossRef Peters E, Dieckmann N, Dixon A, Hibbard JH, Mertz CK. Less is more in presenting quality information to consumers. Med Care ResRev MCRR. 2007;64:169–90.CrossRef
72.•
Zurück zum Zitat Shrank WH, Parker R, Davis T, Pandit AU, Knox JP, Moraras P, et al. Rationale and design of a randomized trial to evaluate an evidence-based prescription drug label on actual medication use. Contemp Clin Trials. 2010;31:564–71. This study examines patient beliefs about effective communications about their medical regimens.PubMedCrossRef Shrank WH, Parker R, Davis T, Pandit AU, Knox JP, Moraras P, et al. Rationale and design of a randomized trial to evaluate an evidence-based prescription drug label on actual medication use. Contemp Clin Trials. 2010;31:564–71. This study examines patient beliefs about effective communications about their medical regimens.PubMedCrossRef
73.•
Zurück zum Zitat Misono AS, Cutrona SL, Choudhry NK, Fischer MA, Stedman MR, et al. Healthcare information technology interventions to improve cardiovascular and diabetes medication adherence. Am J Manag Care. 2010;16:SP82–92. This study explores the impact of health information technology based interventions on medication adherence.PubMed Misono AS, Cutrona SL, Choudhry NK, Fischer MA, Stedman MR, et al. Healthcare information technology interventions to improve cardiovascular and diabetes medication adherence. Am J Manag Care. 2010;16:SP82–92. This study explores the impact of health information technology based interventions on medication adherence.PubMed
74.••
Zurück zum Zitat Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey Jr DE, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:e426–579. These are the 2011 guidelines for patients with non-ST segment elevation acute coronary syndromes.PubMedCrossRef Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey Jr DE, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:e426–579. These are the 2011 guidelines for patients with non-ST segment elevation acute coronary syndromes.PubMedCrossRef
75.•
Zurück zum Zitat Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardio. 2010;56:254–63. This is a contemporary examination of patterns of care for patients with acute myocardial infarction.CrossRef Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, Dai D, et al. Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. J Am Coll Cardio. 2010;56:254–63. This is a contemporary examination of patterns of care for patients with acute myocardial infarction.CrossRef
Metadaten
Titel
Impediments to Adherence to Post Myocardial Infarction Medications
verfasst von
Nihar R. Desai
Niteesh K. Choudhry
Publikationsdatum
01.01.2013
Verlag
Current Science Inc.
Erschienen in
Current Cardiology Reports / Ausgabe 1/2013
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-012-0322-6

Weitere Artikel der Ausgabe 1/2013

Current Cardiology Reports 1/2013 Zur Ausgabe

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Modeling of Fractional Flow Reserve Based on Coronary CT Angiography

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Transcatheter Aortic Valve Repair, Imaging, and Electronic Imaging Health Record

Cardiac PET, CT, and MRI (S Achenbach, Section Editor)

Coronary Calcium: New Insights, Recent Data, and Clinical Role

Diabetes and Cardiovascular Disease (S Malik, Section Editor)

Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.